Roughly 30,000 Americans are diagnosed with multiple myeloma each year—a rare but serious cancer of the plasma cells. Historically treated with chemotherapy, patients often faced recurring disease and…
Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
NEW YORK (Reuters Health) – Despite declining use, perineal radical prostatectomy (PRP) yields outcomes that are equal to, or better than, those of retropubic radical prostatectomy (RRP) and…
Join us for Meetings in Minutes – AHA Scientific Sessions 2010 – Extended Meeting Coverage. In this edition, we bring you extended coverage of the DEFINE trial, featuring…
NEW YORK (Reuters Health) – Outcomes of cryoablation of small renal masses are similar whether the procedure is performed surgically or percutaneously, according the results of a meta-analysis…
NEW YORK (Reuters Health) – In terms of overall survival, carboplatin plus the oral fluoropyrimidine derivative S-1 is as effective as carboplatin plus paclitaxel in chemotherapy-naive patients with…
Join us for Meetings in Minutes – AHA Scientific Sessions 2010 – Day 4. Our fourth and final daily wrap-up features highlights from the key late breaking trials,…
Join us for Meetings in Minutes – AHA Scientific Sessions 2010 – Day 3. Our third daily wrap-up features highlights from the key late breaking trials, and some…
Join us for Meetings in Minutes – AHA Scientific Sessions 2010 – Day 2. Our second daily wrap-up features highlights from the key late breaking trials, and some…
Join us for Meetings in Minutes – AHA Scientific Sessions 2010 – Day 1. Our first day wrap-up features highlights from the presidential address, the key late breaking…
Did you miss AMA’s 2010 Interim Meeting of the House of Delegates? Don’t worry, The Doctor’s Channel has you covered. Get all of the highlights from the meeting…
NEW YORK (Reuters Health) – Compared with zoledronic acid, the monoclonal antibody denosumab is more effective in delaying skeletal-related events in women with breast cancer that has metastasized…
